{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:31:08Z","timestamp":1786591868483,"version":"build-2736575974"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA272686"],"award-info":[{"award-number":["CA272686"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Von Hippel-Lindau disease (VHLD) is a rare autosomal dominant disease, occuring in\u2009~\u20091 in 35,000 individuals. Overall, individuals with inherited mutations in the\n                    <jats:italic>VHL<\/jats:italic>\n                    tumor suppressor gene are predisposed to a variety of cancer, including high frequencies of clear cell renal cell carcinoma (ccRCC), pancreatic neuroendocrine tumors, and hemangioblastomas, as well as benign cystic conditions and other cancers. The degree of risk for each of these pathological conditions depends on the location and severity of the inherited germline mutation, and the specific VHL protein interactions and functions disrupted. A core VHL protein function is as the targeting subunit of an E3 ligase complex, with protein degradation activity based on interactions with elongins (ELOB, ELOC), Cullin 2 (CUL2), and RBX1. For ccRCC and some other cancers, loss of VHL-dependent degradation of key substrates\u2014the transcription factors hypoxia-inducible factor alpha (HIF-1\u03b1 and HIF-2\u03b1)\u2014and upregulation of HIF-dependent transcripts are critical to promote tumor formation. For this reason, drugs such as the HIF signaling inhibitor belzutifan have emerged as promising clinical agents for treatment of VHLD patients prone to ccRCC. However, other biological consequences of VHL loss are independent of HIF\u03b1 degradation, and in some cases independent of the VHL ubiquitin ligase activity. Non-canonical activities of VHL include regulation of microtubule stability, mitotic progression, and ciliation, as well as formation of the extracellular matrix (ECM); the degree to which disruption of these activities contributes to VHLD is currently not well understood. This review provides a concise update of the current literature on VHLD pathogenesis, the relationship of VHL structure and protein interactions to the spectrum of phenotypes associated with VHLD, and current and proposed treatment, prevention, and interception of cancer formation for VHLD patients.\n                  <\/jats:p>","DOI":"10.1007\/s10555-026-10370-x","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:22:50Z","timestamp":1786591370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD)"],"prefix":"10.1007","volume":"45","author":[{"given":"Shabnam","family":"Pirestani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Broadrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margie L.","family":"Clapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Golemis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"10370_CR1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162480","author":"WG Kaelin Jr.","year":"2022","unstructured":"Kaelin, W. G., Jr. (2022). Von Hippel-Lindau disease: Insights into oxygen sensing, protein degradation, and cancer. Journal of Clinical Investigation. https:\/\/doi.org\/10.1172\/JCI162480","journal-title":"Journal of Clinical Investigation"},{"issue":"8","key":"10370_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2022.104538","volume":"65","author":"MBM Louise","year":"2022","unstructured":"Louise, M. B. M., Smerdel, M., Borgwadt, L., Beck Nielsen, S. S., Madsen, M. G., Moller, H. U., et al. (2022). von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. European Journal of Medical Genetics, 65(8), Article 104538. https:\/\/doi.org\/10.1016\/j.ejmg.2022.104538","journal-title":"European Journal of Medical Genetics"},{"issue":"3","key":"10370_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/hmg\/ddad181","volume":"33","author":"A Serghini","year":"2024","unstructured":"Serghini, A., Portelli, S., Troadec, G., Song, C., Pan, Q., Pires, D. E. V., et al. (2024). Characterizing and predicting ccRCC-causing missense mutations in Von Hippel-Lindau disease. Human Molecular Genetics, 33(3), 224\u2013232. https:\/\/doi.org\/10.1093\/hmg\/ddad181","journal-title":"Human Molecular Genetics"},{"issue":"9","key":"10370_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41585-024-00874-y","volume":"21","author":"A Larcher","year":"2024","unstructured":"Larcher, A., Belladelli, F., Cei, F., Re, C., Rowe, I., Montorsi, F., et al. (2024). Centralization of care for rare genetic syndromes associated with cancer: Improving outcomes and advancing research on VHL disease. Nature Reviews Urology, 21(9), 565\u2013571. https:\/\/doi.org\/10.1038\/s41585-024-00874-y","journal-title":"Nature Reviews Urology"},{"issue":"1","key":"10370_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13023-024-03060-w","volume":"19","author":"E Jonasch","year":"2024","unstructured":"Jonasch, E., Song, Y., Freimark, J., Berman, R., Nguyen, H., Signorovitch, J., et al. (2024). Epidemiology and economic burden of Von Hippel-Lindau disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States. Orphanet Journal of Rare Diseases, 19(1), 73. https:\/\/doi.org\/10.1186\/s13023-024-03060-w","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"5","key":"10370_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/humu.21219","volume":"31","author":"M Nordstrom-O'Brien","year":"2010","unstructured":"Nordstrom-O\u2019Brien, M., van der Luijt, R. B., van Rooijen, E., van den Ouweland, A. M., Majoor-Krakauer, D. F., Lolkema, M. P., et al. (2010). Genetic analysis of von Hippel-Lindau disease. Human Mutation, 31(5), 521\u2013537. https:\/\/doi.org\/10.1002\/humu.21219","journal-title":"Human Mutation"},{"issue":"1","key":"10370_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12886-024-03597-1","volume":"24","author":"F Azimi","year":"2024","unstructured":"Azimi, F., Naseripour, M., Aghajani, A., Kasraei, H., & Chaibakhsh, S. (2024). The genetic differences between types 1 and 2 in von Hippel-Lindau syndrome: Comprehensive meta-analysis. BMC Ophthalmology, 24(1), 343. https:\/\/doi.org\/10.1186\/s12886-024-03597-1","journal-title":"BMC Ophthalmology"},{"issue":"12","key":"10370_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jama.2024.12848","volume":"332","author":"TL Rose","year":"2024","unstructured":"Rose, T. L., & Kim, W. Y. (2024). Renal cell carcinoma: A review. JAMA, 332(12), 1001\u20131010. https:\/\/doi.org\/10.1001\/jama.2024.12848","journal-title":"JAMA"},{"issue":"4","key":"10370_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/cas.15728","volume":"114","author":"H Takamori","year":"2023","unstructured":"Takamori, H., Yamasaki, T., Kitadai, R., Minamishima, Y. A., & Nakamura, E. (2023). Development of drugs targeting hypoxia-inducible factor against tumor cells with VHL mutation: Story of 127 years. Cancer science, 114(4), 1208\u20131217. https:\/\/doi.org\/10.1111\/cas.15728","journal-title":"Cancer science"},{"key":"10370_CR10","doi-asserted-by":"publisher","unstructured":"Mazumder, S., Higgins, P. J., & Samarakoon, R. (2023). Downstream targets of VHL\/HIF-alpha signaling in renal clear cell carcinoma progression: mechanisms and therapeutic relevance. Cancers (Basel), 15(4). https:\/\/doi.org\/10.3390\/cancers15041316","DOI":"10.3390\/cancers15041316"},{"key":"10370_CR11","doi-asserted-by":"publisher","unstructured":"Wolf, M. M., Madden, M. Z., Arner, E. N., Bader, J. E., Ye, X., Vlach, L., et al. (2024). VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis. The Journal of Clinical Investigation, 134(8). https:\/\/doi.org\/10.1172\/JCI173934","DOI":"10.1172\/JCI173934"},{"key":"10370_CR12","doi-asserted-by":"publisher","unstructured":"Oxburgh, L. (2022). The extracellular matrix environment of clear cell renal cell carcinoma. Cancers (Basel), 14(17). https:\/\/doi.org\/10.3390\/cancers14174072","DOI":"10.3390\/cancers14174072"},{"issue":"48","key":"10370_CR13","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1038\/sj.onc.1203938","volume":"19","author":"M Krieg","year":"2000","unstructured":"Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H. (2000). Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene, 19(48), 5435\u20135443. https:\/\/doi.org\/10.1038\/sj.onc.1203938","journal-title":"Oncogene"},{"issue":"1","key":"10370_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031034","volume":"7","author":"RE Schietke","year":"2012","unstructured":"Schietke, R. E., Hackenbeck, T., Tran, M., Gunther, R., Klanke, B., Warnecke, C. L., et al. (2012). Renal tubular HIF-2alpha expression requires VHL inactivation and causes fibrosis and cysts. PLoS ONE, 7(1), Article e31034. https:\/\/doi.org\/10.1371\/journal.pone.0031034","journal-title":"PLoS ONE"},{"issue":"3","key":"10370_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","volume":"3","author":"JW Kim","year":"2006","unstructured":"Kim, J. W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism, 3(3), 177\u2013185. https:\/\/doi.org\/10.1016\/j.cmet.2006.02.002","journal-title":"Cell Metabolism"},{"issue":"6","key":"10370_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1158\/2159-8290.CD-14-1507","volume":"5","author":"B Qiu","year":"2015","unstructured":"Qiu, B., Ackerman, D., Sanchez, D. J., Li, B., Ochocki, J. D., Grazioli, A., et al. (2015). HIF2alpha-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discovery, 5(6), 652\u2013667. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-1507","journal-title":"Cancer Discovery"},{"key":"10370_CR17","doi-asserted-by":"publisher","unstructured":"Bakleh, M. Z., & Al Haj Zen, A. (2025). The Distinct Role of HIF-1alpha and HIF-2alpha in Hypoxia and Angiogenesis. Cells, 14(9). https:\/\/doi.org\/10.3390\/cells14090673","DOI":"10.3390\/cells14090673"},{"issue":"12","key":"10370_CR18","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1158\/0008-5472.CAN-05-2519","volume":"66","author":"VA Carroll","year":"2006","unstructured":"Carroll, V. A., & Ashcroft, M. (2006). Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: Implications for targeting the HIF pathway. Cancer Research, 66(12), 6264\u20136270. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2519","journal-title":"Cancer Research"},{"issue":"13","key":"10370_CR19","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","volume":"25","author":"RR Raval","year":"2005","unstructured":"Raval, R. R., Lau, K. W., Tran, M. G., Sowter, H. M., Mandriota, S. J., Li, J. L., et al. (2005). Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Molecular and Cellular Biology, 25(13), 5675\u20135686. https:\/\/doi.org\/10.1128\/MCB.25.13.5675-5686.2005","journal-title":"Molecular and Cellular Biology"},{"issue":"4","key":"10370_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ccr.2007.02.006","volume":"11","author":"JD Gordan","year":"2007","unstructured":"Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A., & Simon, M. C. (2007). HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell, 11(4), 335\u2013347. https:\/\/doi.org\/10.1016\/j.ccr.2007.02.006","journal-title":"Cancer Cell"},{"issue":"6","key":"10370_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","volume":"14","author":"JD Gordan","year":"2008","unstructured":"Gordan, J. D., Lal, P., Dondeti, V. R., Letrero, R., Parekh, K. N., Oquendo, C. E., et al. (2008). HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell, 14(6), 435\u2013446. https:\/\/doi.org\/10.1016\/j.ccr.2008.10.016","journal-title":"Cancer Cell"},{"issue":"7","key":"10370_CR22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2310479121","volume":"121","author":"L Sainero-Alcolado","year":"2024","unstructured":"Sainero-Alcolado, L., Garde-Lapido, E., Snaebjornsson, M. T., Schoch, S., Stevens, I., Ruiz-Perez, M. V., et al. (2024). Targeting MYC induces lipid droplet accumulation by upregulation of HILPDA in clear cell renal cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 121(7), Article e2310479121. https:\/\/doi.org\/10.1073\/pnas.2310479121","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10370_CR23","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/s41588-024-01800-z","volume":"56","author":"M Buckley","year":"2024","unstructured":"Buckley, M., Terwagne, C., Ganner, A., Cubitt, L., Brewer, R., Kim, D. K., et al. (2024). Saturation genome editing maps the functional spectrum of pathogenic VHL alleles. Nature Genetics, 56(7), 1446\u20131455. https:\/\/doi.org\/10.1038\/s41588-024-01800-z","journal-title":"Nature Genetics"},{"issue":"5112","key":"10370_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F. M., Orcutt, M. L., et al. (1993). Identification of the von Hippel-Lindau disease tumor suppressor gene. Science, 260(5112), 1317\u20131320. https:\/\/doi.org\/10.1126\/science.8493574","journal-title":"Science"},{"issue":"20","key":"10370_CR25","doi-asserted-by":"publisher","first-page":"11661","DOI":"10.1073\/pnas.95.20.11661","volume":"95","author":"O Iliopoulos","year":"1998","unstructured":"Iliopoulos, O., Ohh, M., & Kaelin, W. G., Jr. (1998). pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proceedings of the National Academy of Sciences of the United States of America, 95(20), 11661\u201311666. https:\/\/doi.org\/10.1073\/pnas.95.20.11661","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"15","key":"10370_CR26","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1073\/pnas.95.15.8817","volume":"95","author":"A Schoenfeld","year":"1998","unstructured":"Schoenfeld, A., Davidowitz, E. J., & Burk, R. D. (1998). A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America, 95(15), 8817\u20138822. https:\/\/doi.org\/10.1073\/pnas.95.15.8817","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5413","key":"10370_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1126\/science.284.5413.455","volume":"284","author":"CE Stebbins","year":"1999","unstructured":"Stebbins, C. E., Kaelin, W. G., Jr., & Pavletich, N. P. (1999). Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function. Science, 284(5413), 455\u2013461. https:\/\/doi.org\/10.1126\/science.284.5413.455","journal-title":"Science"},{"issue":"5574","key":"10370_CR28","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1126\/science.1073440","volume":"296","author":"JH Min","year":"2002","unstructured":"Min, J. H., Yang, H., Ivan, M., Gertler, F., Kaelin, W. G., Jr., & Pavletich, N. P. (2002). Structure of an HIF-1alpha -pVHL complex: Hydroxyproline recognition in signaling. Science, 296(5574), 1886\u20131889. https:\/\/doi.org\/10.1126\/science.1073440","journal-title":"Science"},{"issue":"6892","key":"10370_CR29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nature00767","volume":"417","author":"WC Hon","year":"2002","unstructured":"Hon, W. C., Wilson, M. I., Harlos, K., Claridge, T. D., Schofield, C. J., Pugh, C. W., et al. (2002). Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature, 417(6892), 975\u2013978. https:\/\/doi.org\/10.1038\/nature00767","journal-title":"Nature"},{"issue":"3","key":"10370_CR30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.str.2014.12.014","volume":"23","author":"HC Nguyen","year":"2015","unstructured":"Nguyen, H. C., Yang, H., Fribourgh, J. L., Wolfe, L. S., & Xiong, Y. (2015). Insights into Cullin-RING E3 ubiquitin ligase recruitment: Structure of the VHL-EloBC-Cul2 complex. Structure, 23(3), 441\u2013449. https:\/\/doi.org\/10.1016\/j.str.2014.12.014","journal-title":"Structure"},{"issue":"6","key":"10370_CR31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.str.2017.04.009","volume":"25","author":"TAF Cardote","year":"2017","unstructured":"Cardote, T. A. F., Gadd, M. S., & Ciulli, A. (2017). Crystal structure of the Cul2-Rbx1-EloBC-VHL ubiquitin ligase complex. Structure, 25(6), 901-911 e903. https:\/\/doi.org\/10.1016\/j.str.2017.04.009","journal-title":"Structure"},{"issue":"33","key":"10370_CR32","doi-asserted-by":"publisher","first-page":"30388","DOI":"10.1074\/jbc.M203344200","volume":"277","author":"T Kamura","year":"2002","unstructured":"Kamura, T., Brower, C. S., Conaway, R. C., & Conaway, J. W. (2002). A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase. The Journal of biological chemistry, 277(33), 30388\u201330393. https:\/\/doi.org\/10.1074\/jbc.M203344200","journal-title":"The Journal of biological chemistry"},{"issue":"1","key":"10370_CR33","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1038\/s41467-018-05554-1","volume":"9","author":"D Tarade","year":"2018","unstructured":"Tarade, D., Robinson, C. M., Lee, J. E., & Ohh, M. (2018). HIF-2alpha-pVHL complex reveals broad genotype-phenotype correlations in HIF-2alpha-driven disease. Nature Communications, 9(1), 3359. https:\/\/doi.org\/10.1038\/s41467-018-05554-1","journal-title":"Nature Communications"},{"issue":"7","key":"10370_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/35017054","volume":"2","author":"M Ohh","year":"2000","unstructured":"Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T. Y., Huang, L. E., et al. (2000). Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nature Cell Biology, 2(7), 423\u2013427. https:\/\/doi.org\/10.1038\/35017054","journal-title":"Nature Cell Biology"},{"issue":"10","key":"10370_CR35","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","volume":"26","author":"TK Choueiri","year":"2020","unstructured":"Choueiri, T. K., & Kaelin, W. G., Jr. (2020). Targeting the HIF2-VEGF axis in renal cell carcinoma. Nature Medicine, 26(10), 1519\u20131530. https:\/\/doi.org\/10.1038\/s41591-020-1093-z","journal-title":"Nature Medicine"},{"issue":"2","key":"10370_CR36","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1073\/pnas.0808092106","volume":"106","author":"TH Scheuermann","year":"2009","unstructured":"Scheuermann, T. H., Tomchick, D. R., Machius, M., Guo, Y., Bruick, R. K., & Gardner, K. H. (2009). Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor. Proceedings of the National Academy of Sciences of the United States of America, 106(2), 450\u2013455. https:\/\/doi.org\/10.1073\/pnas.0808092106","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10370_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nchembio.1185","volume":"9","author":"TH Scheuermann","year":"2013","unstructured":"Scheuermann, T. H., Li, Q., Ma, H. W., Key, J., Zhang, L., Chen, R., et al. (2013). Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nature Chemical Biology, 9(4), 271\u2013276. https:\/\/doi.org\/10.1038\/nchembio.1185","journal-title":"Nature Chemical Biology"},{"issue":"22","key":"10370_CR38","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., et al. (2021). Belzutifan for renal cell carcinoma in von hippel-lindau disease. The New England Journal of Medicine, 385(22), 2036\u20132046. https:\/\/doi.org\/10.1056\/NEJMoa2103425","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10370_CR39","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1470-2045(24)00389-9","volume":"25","author":"O Iliopoulos","year":"2024","unstructured":"Iliopoulos, O., Iversen, A. B., Narayan, V., Maughan, B. L., Beckermann, K. E., Oudard, S., et al. (2024). Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): A multicentre, single-arm, phase 2 study. The Lancet Oncology, 25(10), 1325\u20131336. https:\/\/doi.org\/10.1016\/S1470-2045(24)00389-9","journal-title":"The Lancet Oncology"},{"issue":"9","key":"10370_CR40","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1158\/1078-0432.CCR-23-2592","volume":"30","author":"T Else","year":"2024","unstructured":"Else, T., Jonasch, E., Iliopoulos, O., Beckermann, K. E., Narayan, V., Maughan, B. L., et al. (2024). Belzutifan for von Hippel-Lindau disease: Pancreatic lesion population of the phase 2 LITESPARK-004 study. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 30(9), 1750\u20131757. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2592","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"20","key":"10370_CR41","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa2504964","volume":"393","author":"C Jimenez","year":"2025","unstructured":"Jimenez, C., Andreassen, M., Durand, A., Moog, S., Hendifar, A., Welin, S., et al. (2025). Belzutifan for advanced pheochromocytoma or paraganglioma. New England Journal of Medicine, 393(20), 2012\u20132022. https:\/\/doi.org\/10.1056\/NEJMoa2504964","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10370_CR42","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(25)00099-3","volume":"26","author":"R Srinivasan","year":"2025","unstructured":"Srinivasan, R., Iliopoulos, O., Beckermann, K. E., Narayan, V., Maughan, B. L., Oudard, S., et al. (2025). Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. The Lancet Oncology, 26(5), 571\u2013582. https:\/\/doi.org\/10.1016\/S1470-2045(25)00099-3","journal-title":"The Lancet Oncology"},{"issue":"1","key":"10370_CR43","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1186\/s12885-025-15192-8","volume":"25","author":"K Rhein","year":"2025","unstructured":"Rhein, K., Kotsis, F., Ganner, A., Astheimer, S., Gizaw, C. J., Laich, Y., et al. (2025). Belzutifan for patients with Von Hippel-Lindau (VHL) disease-associated heterogeneous tumors - a retrospective single center analysis. BMC Cancer, 25(1), 1686. https:\/\/doi.org\/10.1186\/s12885-025-15192-8","journal-title":"BMC Cancer"},{"key":"10370_CR44","doi-asserted-by":"publisher","unstructured":"Sundaram, M., Atkinson, C., Cooper, C., Taylor-Stokes, G., Mann, J., & Iliopoulos, O. (2025). The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey. The Oncologist, 30(9). https:\/\/doi.org\/10.1093\/oncolo\/oyaf206.","DOI":"10.1093\/oncolo\/oyaf206"},{"issue":"8","key":"10370_CR45","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K., Powles, T., Peltola, K., de Velasco, G., Burotto, M., Suarez, C., et al. (2024). Belzutifan versus everolimus for advanced renal-cell carcinoma. The New England Journal of Medicine, 391(8), 710\u2013721. https:\/\/doi.org\/10.1056\/NEJMoa2313906","journal-title":"The New England Journal of Medicine"},{"key":"10370_CR46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1199","author":"J Fallah","year":"2024","unstructured":"Fallah, J., Heiss, B. L., Joeng, H. K., Weinstock, C., Gao, X., Pierce, W. F., et al. (2024). FDA approval summary: Belzutifan for patients with advanced renal cell carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1199","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"10370_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","volume":"26","author":"TK Choueiri","year":"2025","unstructured":"Choueiri, T. K., Merchan, J. R., Figlin, R., McDermott, D. F., Arrowsmith, E., Michaelson, M. D., et al. (2025). Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): An open-label, single-arm, phase 2 study. The Lancet Oncology, 26(1), 64\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(24)00649-1","journal-title":"The Lancet Oncology"},{"issue":"7","key":"10370_CR48","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1158\/2159-8290.CD-24-1378","volume":"15","author":"NH Shirole","year":"2025","unstructured":"Shirole, N. H., Kesar, D., Lee, Y., Goodale, A., Syamala, S., Kukreja, S., et al. (2025). Requirement for cyclin D1 underlies cell-autonomous HIF2 dependence in kidney cancer. Cancer Discovery, 15(7), 1484\u20131504. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1378","journal-title":"Cancer Discovery"},{"key":"10370_CR49","doi-asserted-by":"publisher","unstructured":"Bacigalupa, Z. A., Arner, E. N., Vlach, L. M., Wolf, M. M., Brown, W. A., Krystofiak, E. S., et al. (2024). HIF-2alpha expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma. The Journal of Clinical Investigation, 134(12). https:\/\/doi.org\/10.1172\/JCI164249.","DOI":"10.1172\/JCI164249"},{"issue":"1","key":"10370_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1188\/25.CJON.25-29","volume":"29","author":"H Niccum Haag","year":"2025","unstructured":"Niccum Haag, H. (2025). A new era of management of von Hippel-Lindau disease-associated tumors with belzutifan. Clinical Journal of Oncology Nursing, 29(1), 25\u201329. https:\/\/doi.org\/10.1188\/25.CJON.25-29","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"1","key":"10370_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00280-025-04861-x","volume":"96","author":"I Karaman","year":"2026","unstructured":"Karaman, I., Erdem, D., & Cetin, B. (2026). First-in-class HIF-2alpha therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 96(1), 13. https:\/\/doi.org\/10.1007\/s00280-025-04861-x","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"5","key":"10370_CR52","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s11096-025-01953-9","volume":"47","author":"Y Ye","year":"2025","unstructured":"Ye, Y., Fan, B., & Hu, X. (2025). A real-world pharmacovigilance study of belzutifan in renal cell carcinoma and von Hippel-Lindau disease: Insights from the FDA adverse event reporting system database. International Journal of Clinical Pharmacy, 47(5), 1447\u20131457. https:\/\/doi.org\/10.1007\/s11096-025-01953-9","journal-title":"International Journal of Clinical Pharmacy"},{"issue":"12","key":"10370_CR53","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1002\/bcp.70169","volume":"91","author":"M Ghasemi","year":"2025","unstructured":"Ghasemi, M., Kim, J. Y., Seitz, L., Jin, L., Foster, P. G., Liao, K. H., et al. (2025). Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia-inducible factor-2alpha inhibitor, in healthy participants. British Journal of Clinical Pharmacology, 91(12), 3366\u20133377. https:\/\/doi.org\/10.1002\/bcp.70169","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"17","key":"10370_CR54","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1111\/bph.70075","volume":"182","author":"PG Schweickert","year":"2025","unstructured":"Schweickert, P. G., Piovesan, D., Mitchell, C. G., Zepeda-Carranza, B., Zhu, W. S., Lopez Espinoza, A. Y., et al. (2025). Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2alpha dependent transcription. British Journal of Pharmacology, 182(17), 4147\u20134167. https:\/\/doi.org\/10.1111\/bph.70075","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10370_CR55","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/ncb899","volume":"5","author":"A Hergovich","year":"2003","unstructured":"Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P., & Krek, W. (2003). Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nature Cell Biology, 5(1), 64\u201370. https:\/\/doi.org\/10.1038\/ncb899","journal-title":"Nature Cell Biology"},{"issue":"15","key":"10370_CR56","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1128\/MCB.00232-06","volume":"26","author":"A Hergovich","year":"2006","unstructured":"Hergovich, A., Lisztwan, J., Thoma, C. R., Wirbelauer, C., Barry, R. E., & Krek, W. (2006). Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. Molecular and Cellular Biology, 26(15), 5784\u20135796. https:\/\/doi.org\/10.1128\/MCB.00232-06","journal-title":"Molecular and Cellular Biology"},{"issue":"6","key":"10370_CR57","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1083\/jcb.201006059","volume":"190","author":"CR Thoma","year":"2010","unstructured":"Thoma, C. R., Matov, A., Gutbrodt, K. L., Hoerner, C. R., Smole, Z., Krek, W., et al. (2010). Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability. Journal of Cell Biology, 190(6), 991\u20131003. https:\/\/doi.org\/10.1083\/jcb.201006059","journal-title":"Journal of Cell Biology"},{"issue":"8","key":"10370_CR58","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/ncb1912","volume":"11","author":"CR Thoma","year":"2009","unstructured":"Thoma, C. R., Toso, A., Gutbrodt, K. L., Reggi, S. P., Frew, I. J., Schraml, P., et al. (2009). VHL loss causes spindle misorientation and chromosome instability. Nature Cell Biology, 11(8), 994\u20131001. https:\/\/doi.org\/10.1038\/ncb1912","journal-title":"Nature Cell Biology"},{"issue":"9","key":"10370_CR59","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1158\/0008-5472.CAN-13-2040","volume":"74","author":"MP Hell","year":"2014","unstructured":"Hell, M. P., Duda, M., Weber, T. C., Moch, H., & Krek, W. (2014). Tumor suppressor VHL functions in the control of mitotic fidelity. Cancer Research, 74(9), 2422\u20132431. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2040","journal-title":"Cancer Research"},{"issue":"Pt 13","key":"10370_CR60","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1242\/jcs.087122","volume":"124","author":"S Sinha","year":"2011","unstructured":"Sinha, S., Mondal, G., Hwang, E. J., da Han, W., Dutta, S. K., Iyer, S., et al. (2011). Von Hippel-Lindau gene product directs cytokinesis: A new tumor suppressor function. Journal of Cell Science, 124(Pt 13), 2132\u20132142. https:\/\/doi.org\/10.1242\/jcs.087122","journal-title":"Journal of Cell Science"},{"issue":"7","key":"10370_CR61","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1681\/ASN.2006020181","volume":"17","author":"MA Esteban","year":"2006","unstructured":"Esteban, M. A., Harten, S. K., Tran, M. G., & Maxwell, P. H. (2006). Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. Journal of the American Society of Nephrology\u202f: JASN, 17(7), 1801\u20131806. https:\/\/doi.org\/10.1681\/ASN.2006020181","journal-title":"Journal of the American Society of Nephrology : JASN"},{"issue":"14","key":"10370_CR62","doi-asserted-by":"publisher","first-page":"6903","DOI":"10.1158\/0008-5472.CAN-06-0501","volume":"66","author":"MS Lutz","year":"2006","unstructured":"Lutz, M. S., & Burk, R. D. (2006). Primary cilium formation requires von Hippel-Lindau gene function in renal-derived cells. Cancer Research, 66(14), 6903\u20136907.","journal-title":"Cancer Research"},{"key":"10370_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1052-z","author":"J Pan","year":"2012","unstructured":"Pan, J., Seeger-Nukpezah, T., & Golemis, E. A. (2012). The role of the cilium in normal and abnormal cell cycles: Emphasis on renal cystic pathologies. Cellular and Molecular Life Sciences: CMLS. https:\/\/doi.org\/10.1007\/s00018-012-1052-z","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"issue":"8","key":"10370_CR64","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41568-018-0023-6","volume":"18","author":"H Liu","year":"2018","unstructured":"Liu, H., Kiseleva, A. A., & Golemis, E. A. (2018). Ciliary signalling in cancer. Nature Reviews. Cancer, 18(8), 511\u2013524. https:\/\/doi.org\/10.1038\/s41568-018-0023-6","journal-title":"Nature Reviews. Cancer"},{"issue":"6","key":"10370_CR65","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s12192-021-01240-2","volume":"26","author":"MR Woodford","year":"2021","unstructured":"Woodford, M. R., Backe, S. J., Wengert, L. A., Dunn, D. M., Bourboulia, D., & Mollapour, M. (2021). Hsp90 chaperone code and the tumor suppressor VHL cooperatively regulate the mitotic checkpoint. Cell Stress & Chaperones, 26(6), 965\u2013971. https:\/\/doi.org\/10.1007\/s12192-021-01240-2","journal-title":"Cell Stress & Chaperones"},{"issue":"10","key":"10370_CR66","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/ncb1309","volume":"7","author":"EN Pugacheva","year":"2005","unstructured":"Pugacheva, E. N., & Golemis, E. A. (2005). The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nature Cell Biology, 7(10), 937\u2013946.","journal-title":"Nature Cell Biology"},{"key":"10370_CR67","doi-asserted-by":"publisher","unstructured":"Xu, J., Li, H., Wang, B., Xu, Y., Yang, J., Zhang, X., et al. (2010). VHL Inactivation Induces HEF1 and Aurora Kinase A. Journal of the American Society of Nephrology : JASN, ASN.2010040345[pii]. https:\/\/doi.org\/10.1681\/ASN.2010040345","DOI":"10.1681\/ASN.2010040345"},{"issue":"3","key":"10370_CR68","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1681\/ASN.2013090984","volume":"26","author":"R Dere","year":"2015","unstructured":"Dere, R., Perkins, A. L., Bawa-Khalfe, T., Jonasch, D., & Walker, C. L. (2015). Beta-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma. Journal of the American Society of Nephrology: JASN, 26(3), 553\u2013564. https:\/\/doi.org\/10.1681\/ASN.2013090984","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"24","key":"10370_CR69","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1038\/onc.2016.495","volume":"36","author":"E Hasanov","year":"2017","unstructured":"Hasanov, E., Chen, G., Chowdhury, P., Weldon, J., Ding, Z., Jonasch, E., et al. (2017). Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL. Oncogene, 36(24), 3450\u20133463. https:\/\/doi.org\/10.1038\/onc.2016.495","journal-title":"Oncogene"},{"key":"10370_CR70","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200605092","author":"B Schermer","year":"2006","unstructured":"Schermer, B., Ghenoiu, C., Bartram, M., Muller, R. U., Kotsis, F., Hohne, M., et al. (2006). The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth. The Journal of Cell Biology. https:\/\/doi.org\/10.1083\/jcb.200605092","journal-title":"The Journal of Cell Biology"},{"key":"10370_CR71","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.cell.2007.04.035","volume":"129","author":"EN Pugacheva","year":"2007","unstructured":"Pugacheva, E. N., Jablonski, S. A., Hartman, T. R., Henske, E. P., & Golemis, E. A. (2007). HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell, 129, 1351\u20131363.","journal-title":"Cell"},{"issue":"3","key":"10370_CR72","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1074\/jbc.M114.589226","volume":"290","author":"XF Ding","year":"2015","unstructured":"Ding, X. F., Zhou, J., Hu, Q. Y., Liu, S. C., & Chen, G. (2015). The tumor suppressor pVHL down-regulates never-in-mitosis A-related kinase 8 via hypoxia-inducible factors to maintain cilia in human renal cancer cells. Journal of Biological Chemistry, 290(3), 1389\u20131394. https:\/\/doi.org\/10.1074\/jbc.M114.589226","journal-title":"Journal of Biological Chemistry"},{"issue":"6302","key":"10370_CR73","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aad5755","volume":"353","author":"J Guo","year":"2016","unstructured":"Guo, J., Chakraborty, A. A., Liu, P., Gan, W., Zheng, X., Inuzuka, H., et al. (2016). pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science, 353(6302), 929\u2013932. https:\/\/doi.org\/10.1126\/science.aad5755","journal-title":"Science"},{"issue":"1","key":"10370_CR74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.molcel.2007.09.010","volume":"28","author":"H Yang","year":"2007","unstructured":"Yang, H., Minamishima, Y. A., Yan, Q., Schlisio, S., Ebert, B. L., Zhang, X., et al. (2007). pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Molecular Cell, 28(1), 15\u201327. https:\/\/doi.org\/10.1016\/j.molcel.2007.09.010","journal-title":"Molecular Cell"},{"issue":"6399","key":"10370_CR75","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1126\/science.aap8411","volume":"361","author":"J Zhang","year":"2018","unstructured":"Zhang, J., Wu, T., Simon, J., Takada, M., Saito, R., Fan, C., et al. (2018). VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 361(6399), 290\u2013295. https:\/\/doi.org\/10.1126\/science.aap8411","journal-title":"Science"},{"issue":"34","key":"10370_CR76","doi-asserted-by":"publisher","first-page":"16997","DOI":"10.1073\/pnas.1900748116","volume":"116","author":"S Li","year":"2019","unstructured":"Li, S., Rodriguez, J., Li, W., Bullova, P., Fell, S. M., Surova, O., et al. (2019). EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance. Proceedings of the National Academy of Sciences of the United States of America, 116(34), 16997\u201317006. https:\/\/doi.org\/10.1073\/pnas.1900748116","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10370_CR77","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/hmg\/10.10.1019","volume":"10","author":"MA Hoffman","year":"2001","unstructured":"Hoffman, M. A., Ohh, M., Yang, H., Klco, J. M., Ivan, M., & Kaelin, W. G., Jr. (2001). von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Human Molecular Genetics, 10(10), 1019\u20131027. https:\/\/doi.org\/10.1093\/hmg\/10.10.1019","journal-title":"Human Molecular Genetics"},{"issue":"7","key":"10370_CR78","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/s1097-2765(00)80096-9","volume":"1","author":"M Ohh","year":"1998","unstructured":"Ohh, M., Yauch, R. L., Lonergan, K. M., Whaley, J. M., Stemmer-Rachamimov, A. O., Louis, D. N., et al. (1998). The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Molecular Cell, 1(7), 959\u2013968. https:\/\/doi.org\/10.1016\/s1097-2765(00)80096-9","journal-title":"Molecular Cell"},{"issue":"2","key":"10370_CR79","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1006\/bbrc.1999.1347","volume":"263","author":"H Okuda","year":"1999","unstructured":"Okuda, H., Hirai, S., Takaki, Y., Kamada, M., Baba, M., Sakai, N., et al. (1999). Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochemical and Biophysical Research Communications, 263(2), 491\u2013497. https:\/\/doi.org\/10.1006\/bbrc.1999.1347","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"47","key":"10370_CR80","doi-asserted-by":"publisher","first-page":"43611","DOI":"10.1074\/jbc.M107880200","volume":"276","author":"H Okuda","year":"2001","unstructured":"Okuda, H., Saitoh, K., Hirai, S., Iwai, K., Takaki, Y., Baba, M., et al. (2001). The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. The Journal of Biological Chemistry, 276(47), 43611\u201343617. https:\/\/doi.org\/10.1074\/jbc.M107880200","journal-title":"The Journal of Biological Chemistry"},{"issue":"20","key":"10370_CR81","doi-asserted-by":"publisher","first-page":"11178","DOI":"10.1093\/nar\/gkad796","volume":"51","author":"S Park","year":"2023","unstructured":"Park, S., Cho, J. H., Kim, J. H., Park, M., Park, S., Kim, S. Y., et al. (2023). Hypoxia stabilizes SETDB1 to maintain genome stability. Nucleic Acids Research, 51(20), 11178\u201311196. https:\/\/doi.org\/10.1093\/nar\/gkad796","journal-title":"Nucleic Acids Research"},{"issue":"16","key":"10370_CR82","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1093\/emboj\/cdg410","volume":"22","author":"X Na","year":"2003","unstructured":"Na, X., Duan, H. O., Messing, E. M., Schoen, S. R., Ryan, C. K., di Sant\u2019Agnese, P. A., et al. (2003). Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO Journal, 22(16), 4249\u20134259.","journal-title":"EMBO Journal"},{"key":"10370_CR83","doi-asserted-by":"publisher","unstructured":"Zhang, C., Yu, M., Hepperla, A. J., Zhang, Z., Raj, R., Zhong, H., et al. (2024). Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis. The Journal of Clinical Investigation, 134(8). https:\/\/doi.org\/10.1172\/JCI175703.","DOI":"10.1172\/JCI175703"},{"issue":"7","key":"10370_CR84","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.200109","volume":"10","author":"G Minervini","year":"2020","unstructured":"Minervini, G., Pennuto, M., & Tosatto, S. C. E. (2020). The pVHL neglected functions, a tale of hypoxia-dependent and -independent regulations in cancer. Open Biology, 10(7), Article 200109. https:\/\/doi.org\/10.1098\/rsob.200109","journal-title":"Open Biology"},{"issue":"2","key":"10370_CR85","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1582-4934.2010.01238.x","volume":"15","author":"M Li","year":"2011","unstructured":"Li, M., & Kim, W. Y. (2011). Two sides to every story: The HIF-dependent and HIF-independent functions of pVHL. Journal of Cellular and Molecular Medicine, 15(2), 187\u2013195. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01238.x","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"6","key":"10370_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067071","volume":"8","author":"B Martin","year":"2013","unstructured":"Martin, B., Chesnel, F., Delcros, J. G., Jouan, F., Couturier, A., Dugay, F., et al. (2013). Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma (ccRCC). PLoS ONE, 8(6), Article e67071. https:\/\/doi.org\/10.1371\/journal.pone.0067071","journal-title":"PLoS ONE"},{"issue":"4","key":"10370_CR87","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41418-023-01128-x","volume":"30","author":"J Chen","year":"2023","unstructured":"Chen, J., Li, M., Liu, Y., Guan, T., Yang, X., Wen, Y., et al. (2023). PIN1 and CDK1 cooperatively govern pVHL stability and suppressive functions. Cell Death and Differentiation, 30(4), 1082\u20131095. https:\/\/doi.org\/10.1038\/s41418-023-01128-x","journal-title":"Cell Death and Differentiation"},{"issue":"22","key":"10370_CR88","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.4161\/cc.10.22.18096","volume":"10","author":"JS Roe","year":"2011","unstructured":"Roe, J. S., Kim, H. R., Hwang, I. Y., Ha, N. C., Kim, S. T., Cho, E. J., et al. (2011). Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation. Cell Cycle, 10(22), 3920\u20133928. https:\/\/doi.org\/10.4161\/cc.10.22.18096","journal-title":"Cell Cycle"},{"issue":"1","key":"10370_CR89","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4161\/cc.23053","volume":"12","author":"M Patil","year":"2013","unstructured":"Patil, M., Pabla, N., Huang, S., & Dong, Z. (2013). Nek1 phosphorylates Von Hippel-Lindau tumor suppressor to promote its proteasomal degradation and ciliary destabilization. Cell Cycle, 12(1), 166\u2013171. https:\/\/doi.org\/10.4161\/cc.23053","journal-title":"Cell Cycle"},{"issue":"38","key":"10370_CR90","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1038\/onc.2016.40","volume":"35","author":"P German","year":"2016","unstructured":"German, P., Bai, S., Liu, X. D., Sun, M., Zhou, L., Kalra, S., et al. (2016). Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function. Oncogene, 35(38), 4973\u20134980. https:\/\/doi.org\/10.1038\/onc.2016.40","journal-title":"Oncogene"},{"issue":"3","key":"10370_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009720","volume":"5","author":"Q Cai","year":"2010","unstructured":"Cai, Q., Verma, S. C., Kumar, P., Ma, M., & Robertson, E. S. (2010). Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PLoS ONE, 5(3), Article e9720. https:\/\/doi.org\/10.1371\/journal.pone.0009720","journal-title":"PLoS ONE"},{"issue":"5","key":"10370_CR92","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/embor.2008.19","volume":"9","author":"RC Russell","year":"2008","unstructured":"Russell, R. C., & Ohh, M. (2008). NEDD8 acts as a \u201cmolecular switch\u201d defining the functional selectivity of VHL. EMBO Reports, 9(5), 486\u2013491. https:\/\/doi.org\/10.1038\/embor.2008.19","journal-title":"EMBO Reports"},{"issue":"29","key":"10370_CR93","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1038\/s41388-020-1359-4","volume":"39","author":"ER Wolf","year":"2020","unstructured":"Wolf, E. R., Mabry, A. R., Damania, B., & Mayo, L. D. (2020). Mdm2-mediated neddylation of pVHL blocks the induction of antiangiogenic factors. Oncogene, 39(29), 5228\u20135239. https:\/\/doi.org\/10.1038\/s41388-020-1359-4","journal-title":"Oncogene"},{"issue":"8","key":"10370_CR94","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1128\/MCB.24.8.3251-3261.2004","volume":"24","author":"NH Stickle","year":"2004","unstructured":"Stickle, N. H., Chung, J., Klco, J. M., Hill, R. P., Kaelin, W. G., Jr., & Ohh, M. (2004). pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Molecular and Cellular Biology, 24(8), 3251\u20133261. https:\/\/doi.org\/10.1128\/MCB.24.8.3251-3261.2004","journal-title":"Molecular and Cellular Biology"},{"issue":"11","key":"10370_CR95","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1158\/0008-5472.CAN-13-3213","volume":"74","author":"Z Ding","year":"2014","unstructured":"Ding, Z., German, P., Bai, S., Reddy, A. S., Liu, X. D., Sun, M., et al. (2014). Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. Cancer Research, 74(11), 3127\u20133136. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3213","journal-title":"Cancer Research"},{"issue":"5","key":"10370_CR96","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cell.2005.03.024","volume":"121","author":"AJ McClellan","year":"2005","unstructured":"McClellan, A. J., Scott, M. D., & Frydman, J. (2005). Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. Cell, 121(5), 739\u2013748. https:\/\/doi.org\/10.1016\/j.cell.2005.03.024","journal-title":"Cell"},{"issue":"1","key":"10370_CR97","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.celrep.2012.12.007","volume":"3","author":"C Yang","year":"2013","unstructured":"Yang, C., Huntoon, K., Ksendzovsky, A., Zhuang, Z., & Lonser, R. R. (2013). Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. Cell Reports, 3(1), 52\u201359. https:\/\/doi.org\/10.1016\/j.celrep.2012.12.007","journal-title":"Cell Reports"},{"issue":"12","key":"10370_CR98","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1158\/1078-0432.CCR-22-3651","volume":"29","author":"P Chittiboina","year":"2023","unstructured":"Chittiboina, P., Mandal, D., Bugarini, A., Asuzu, D. T., Mullaney, D., Mastorakos, P., et al. (2023). Proteostasis modulation in germline missense von Hippel Lindau disease. Clinical Cancer Research, 29(12), 2199\u20132209. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3651","journal-title":"Clinical Cancer Research"},{"key":"10370_CR99","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02203","author":"H Wu","year":"2024","unstructured":"Wu, H., Murray, J., Ishisoko, N., Frommlet, A., Deshmukh, G., DiPasquale, A., et al. (2024). Potency-enhanced peptidomimetic VHL ligands with improved oral bioavailability. Journal of Medicinal Chemistry. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c02203","journal-title":"Journal of Medicinal Chemistry"},{"key":"10370_CR100","doi-asserted-by":"publisher","first-page":"13312","DOI":"10.1038\/ncomms13312","volume":"7","author":"J Frost","year":"2016","unstructured":"Frost, J., Galdeano, C., Soares, P., Gadd, M. S., Grzes, K. M., Ellis, L., et al. (2016). Potent and selective chemical probe of hypoxic signalling downstream of HIF-alpha hydroxylation via VHL inhibition. Nature Communications, 7, 13312. https:\/\/doi.org\/10.1038\/ncomms13312","journal-title":"Nature Communications"},{"issue":"2","key":"10370_CR101","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1021\/acs.jmedchem.7b00675","volume":"61","author":"P Soares","year":"2018","unstructured":"Soares, P., Gadd, M. S., Frost, J., Galdeano, C., Ellis, L., Epemolu, O., et al. (2018). Group-based optimization of potent and cell-active inhibitors of the von Hippel-Lindau (VHL) E3 ubiquitin ligase: Structure-activity relationships leading to the chemical probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). Journal of Medicinal Chemistry, 61(2), 599\u2013618. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00675","journal-title":"Journal of Medicinal Chemistry"},{"key":"10370_CR102","doi-asserted-by":"publisher","first-page":"17","DOI":"10.12688\/wellcomeopenres.15044.1","volume":"4","author":"J Frost","year":"2019","unstructured":"Frost, J., Ciulli, A., & Rocha, S. (2019). RNA-seq analysis of PHD and VHL inhibitors reveals differences and similarities to the hypoxia response. Wellcome Open Research, 4, 17. https:\/\/doi.org\/10.12688\/wellcomeopenres.15044.1","journal-title":"Wellcome Open Research"},{"issue":"4","key":"10370_CR103","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.bbrc.2018.09.172","volume":"505","author":"S Qiu","year":"2018","unstructured":"Qiu, S., Jia, Y., Tang, J., Liu, X., Hu, H., Wu, T., et al. (2018). Von Hippel-Lindau (VHL) protein antagonist, VH298, promotes functional activities of tendon-derived stem cells and accelerates healing of entheses in rats by inhibiting ubiquitination of hydroxy-HIF-1alpha. Biochemical and Biophysical Research Communications, 505(4), 1063\u20131069. https:\/\/doi.org\/10.1016\/j.bbrc.2018.09.172","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10370_CR104","doi-asserted-by":"publisher","first-page":"1897174","DOI":"10.1155\/2019\/1897174","volume":"2019","author":"S Qiu","year":"2019","unstructured":"Qiu, S., Jia, Y., Sun, Y., Han, P., Xu, J., Wen, G., et al. (2019). Von Hippel-Lindau (VHL) protein antagonist VH298 improves wound healing in streptozotocin-induced hyperglycaemic rats by activating hypoxia-inducible factor- (HIF-) 1 signalling. Journal of Diabetes Research, 2019, 1897174. https:\/\/doi.org\/10.1155\/2019\/1897174","journal-title":"Journal of Diabetes Research"},{"key":"10370_CR105","doi-asserted-by":"publisher","unstructured":"Kim, Y. H., Park, N. Y., Jo, D. S., Bae, J. E., Kim, J. B., Park, K., et al. (2024). Inhibition of VHL by VH298 accelerates pexophagy by activation of HIF-1alpha in HeLa cells. Molecules, 29(2). https:\/\/doi.org\/10.3390\/molecules29020482","DOI":"10.3390\/molecules29020482"},{"key":"10370_CR106","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3389\/fimmu.2020.02040","volume":"11","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q., Wang, L., Jiang, J., Lin, S., Luo, A., Zhao, P., et al. (2020). Critical role of AdipoR1 in regulating Th17 cell differentiation through modulation of HIF-1alpha-dependent glycolysis. Frontiers in Immunology, 11, 2040. https:\/\/doi.org\/10.3389\/fimmu.2020.02040","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10370_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100910","volume":"297","author":"J Frost","year":"2021","unstructured":"Frost, J., Rocha, S., & Ciulli, A. (2021). Von Hippel-Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein. The Journal of Biological Chemistry, 297(2), Article 100910. https:\/\/doi.org\/10.1016\/j.jbc.2021.100910","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10370_CR108","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/humu.1380050109","volume":"5","author":"F Chen","year":"1995","unstructured":"Chen, F., Kishida, T., Yao, M., Hustad, T., Glavac, D., Dean, M., et al. (1995). Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Human Mutation, 5(1), 66\u201375. https:\/\/doi.org\/10.1002\/humu.1380050109","journal-title":"Human Mutation"},{"issue":"2","key":"10370_CR109","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/humu.20385","volume":"28","author":"KR Ong","year":"2007","unstructured":"Ong, K. R., Woodward, E. R., Killick, P., Lim, C., Macdonald, F., & Maher, E. R. (2007). Genotype-phenotype correlations in von Hippel-Lindau disease. Human Mutation, 28(2), 143\u2013149. https:\/\/doi.org\/10.1002\/humu.20385","journal-title":"Human Mutation"},{"key":"10370_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2026.102589","author":"DI Ritter","year":"2026","unstructured":"Ritter, D. I., Badduke, C., Doonanco, K., Kang, H. C., Pesaran, T., Ridd, S., et al. (2026). Multi-platform curation in the development of ACMG\/AMP specifications for Von Hippel-Lindau (VHL) disease. Genetics in Medicine. https:\/\/doi.org\/10.1016\/j.gim.2026.102589","journal-title":"Genetics in Medicine"},{"key":"10370_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00867","volume":"10","author":"B Hong","year":"2019","unstructured":"Hong, B., Ma, K., Zhou, J., Zhang, J., Wang, J., Liu, S., et al. (2019). Frequent mutations of VHL gene and the clinical phenotypes in the largest Chinese cohort with Von Hippel-Lindau disease. Frontiers in Genetics, 10, Article 867. https:\/\/doi.org\/10.3389\/fgene.2019.00867","journal-title":"Frontiers in Genetics"},{"key":"10370_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/srep31128","volume":"6","author":"F Tabaro","year":"2016","unstructured":"Tabaro, F., Minervini, G., Sundus, F., Quaglia, F., Leonardi, E., Piovesan, D., et al. (2016). VHLdb: A database of von Hippel-Lindau protein interactors and mutations. Scientific Reports, 6, Article 31128. https:\/\/doi.org\/10.1038\/srep31128","journal-title":"Scientific Reports"},{"issue":"12","key":"10370_CR113","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1093\/hmg\/ddad039","volume":"32","author":"K Tamura","year":"2023","unstructured":"Tamura, K., Kanazashi, Y., Kawada, C., Sekine, Y., Maejima, K., Ashida, S., et al. (2023). Variant spectrum of von Hippel-Lindau disease and its genomic heterogeneity in Japan. Human Molecular Genetics, 32(12), 2046\u20132054. https:\/\/doi.org\/10.1093\/hmg\/ddad039","journal-title":"Human Molecular Genetics"},{"issue":"4","key":"10370_CR114","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/jmg-2023-109550","volume":"61","author":"G Mougel","year":"2024","unstructured":"Mougel, G., Mohamed, A., Burnichon, N., Giraud, S., Pigny, P., Bressac-de Paillerets, B., et al. (2024). Update of the UMD-VHL database: Classification of 164 challenging variants based on genotype-phenotype correlation among 605 entries. Journal of Medical Genetics, 61(4), 378\u2013384. https:\/\/doi.org\/10.1136\/jmg-2023-109550","journal-title":"Journal of Medical Genetics"},{"issue":"5","key":"10370_CR115","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/cge.13613","volume":"96","author":"Y Salama","year":"2019","unstructured":"Salama, Y., Albanyan, S., Szybowska, M., Bullivant, G., Gallinger, B., Giles, R. H., et al. (2019). Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients. Clinical Genetics, 96(5), 461\u2013467. https:\/\/doi.org\/10.1111\/cge.13613","journal-title":"Clinical Genetics"},{"issue":"4","key":"10370_CR116","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.2136","volume":"11","author":"TN Dallagnol","year":"2023","unstructured":"Dallagnol, T. N., Da Cas, E., Junior, O. R., & Casali-da-Rocha, J. C. (2023). Comprehensive characterization and building of National Registry of von Hippel-Lindau disease in Brazil. Molecular Genetics & Genomic Medicine, 11(4), Article e2136. https:\/\/doi.org\/10.1002\/mgg3.2136","journal-title":"Molecular Genetics & Genomic Medicine"},{"issue":"9","key":"10370_CR117","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/humu.24392","volume":"43","author":"A Chiorean","year":"2022","unstructured":"Chiorean, A., Farncombe, K. M., Delong, S., Andric, V., Ansar, S., Chan, C., et al. (2022). Large scale genotype- and phenotype-driven machine learning in Von Hippel-Lindau disease. Human Mutation, 43(9), 1268\u20131285. https:\/\/doi.org\/10.1002\/humu.24392","journal-title":"Human Mutation"},{"issue":"9","key":"10370_CR118","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1210\/jc.2019-00235","volume":"104","author":"SK Flores","year":"2019","unstructured":"Flores, S. K., Cheng, Z., Jasper, A. M., Natori, K., Okamoto, T., Tanabe, A., et al. (2019). Synonymous but not silent: A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease. The Journal of Clinical Endocrinology and Metabolism, 104(9), 3826\u20133834. https:\/\/doi.org\/10.1210\/jc.2019-00235","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"7","key":"10370_CR119","doi-asserted-by":"publisher","first-page":"eadr6375","DOI":"10.1126\/sciadv.adr6375","volume":"11","author":"J Pal","year":"2025","unstructured":"Pal, J., Riester, M., Ganner, A., Ghosh, A., Dhamija, S., Mookherjee, D., et al. (2025). Nonstop mutations cause loss of renal tumor suppressor proteins VHL and BAP1 and affect multiple stages of protein translation. Science Advances, 11(7), eadr6375. https:\/\/doi.org\/10.1126\/sciadv.adr6375","journal-title":"Science Advances"},{"issue":"2","key":"10370_CR120","doi-asserted-by":"publisher","first-page":"120 e121","DOI":"10.1016\/j.urolonc.2025.10.009","volume":"44","author":"CD Vocke","year":"2026","unstructured":"Vocke, C. D., Ricketts, C. J., O\u2019Brien, L., Lebensohn, A. P., Rathi, N., Nielsen, D., et al. (2026). Multigenerational VHL family characterized by pathogenic germline ELOC variant: Response to belzutifan. Urologic Oncology, 44(2), 120 e121-120 e127. https:\/\/doi.org\/10.1016\/j.urolonc.2025.10.009","journal-title":"Urologic Oncology"},{"issue":"2","key":"10370_CR121","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ccr.2005.06.015","volume":"8","author":"S Lee","year":"2005","unstructured":"Lee, S., Nakamura, E., Yang, H., Wei, W., Linggi, M. S., Sajan, M. P., et al. (2005). Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer. Cancer Cell, 8(2), 155\u2013167. https:\/\/doi.org\/10.1016\/j.ccr.2005.06.015","journal-title":"Cancer Cell"},{"issue":"40","key":"10370_CR122","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2410356121","volume":"121","author":"M Abu-Remaileh","year":"2024","unstructured":"Abu-Remaileh, M., Persky, N. S., Lee, Y., Root, D. E., & Kaelin, W. G., Jr. (2024). Total loss of VHL gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2alpha activity. Proceedings of the National Academy of Sciences of the United States of America, 121(40), Article e2410356121. https:\/\/doi.org\/10.1073\/pnas.2410356121","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10370_CR123","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s44321-025-00361-w","volume":"18","author":"J Ge","year":"2026","unstructured":"Ge, J., Hirosue, S., Castillon, L., Patel, S. A., Wesolowski, L., Dyas, A., et al. (2026). Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities. EMBO Molecular Medicine, 18(2), 599\u2013619. https:\/\/doi.org\/10.1038\/s44321-025-00361-w","journal-title":"EMBO Molecular Medicine"},{"issue":"6264","key":"10370_CR124","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1126\/science.aac7557","volume":"350","author":"VA Blomen","year":"2015","unstructured":"Blomen, V. A., Majek, P., Jae, L. T., Bigenzahn, J. W., Nieuwenhuis, J., Staring, J., et al. (2015). Gene essentiality and synthetic lethality in haploid human cells. Science, 350(6264), 1092\u20131096. https:\/\/doi.org\/10.1126\/science.aac7557","journal-title":"Science"},{"issue":"3","key":"10370_CR125","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., et al. (2017). Defining a cancer dependency map. Cell, 170(3), 564-576 e516. https:\/\/doi.org\/10.1016\/j.cell.2017.06.010","journal-title":"Cell"},{"key":"10370_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-70517-w","author":"JAC Bertlin","year":"2026","unstructured":"Bertlin, J. A. C., Pauzaite, T., Liang, Q., Wit, N., Williamson, J. C., Sia, J. J., et al. (2026). VHL synthetic lethality screens uncover CBF-beta as a negative regulator of STING. Nature Communications. https:\/\/doi.org\/10.1038\/s41467-026-70517-w","journal-title":"Nature Communications"},{"key":"10370_CR127","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aay0482","author":"HE Nicholson","year":"2019","unstructured":"Nicholson, H. E., Tariq, Z., Housden, B. E., Jennings, R. B., Stransky, L. A., Perrimon, N., et al. (2019). HIF-independent synthetic lethality between CDK4\/6 inhibition and VHL loss across species. Science Signaling. https:\/\/doi.org\/10.1126\/scisignal.aay0482","journal-title":"Science Signaling"},{"issue":"14","key":"10370_CR128","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2120403119","volume":"119","author":"LA Stransky","year":"2022","unstructured":"Stransky, L. A., Vigeant, S. M., Huang, B., West, D., Denize, T., Walton, E., et al. (2022). Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proceedings of the National Academy of Sciences of the United States of America, 119(14), Article e2120403119. https:\/\/doi.org\/10.1073\/pnas.2120403119","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10370_CR129","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41585-024-00876-w","volume":"21","author":"C Liao","year":"2024","unstructured":"Liao, C., Hu, L., & Zhang, Q. (2024). Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma. Nature Reviews Urology, 21(11), 662\u2013675. https:\/\/doi.org\/10.1038\/s41585-024-00876-w","journal-title":"Nature Reviews Urology"},{"issue":"6","key":"10370_CR130","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s42255-022-00593-x","volume":"4","author":"S Li","year":"2022","unstructured":"Li, S., Li, W., Yuan, J., Bullova, P., Wu, J., Zhang, X., et al. (2022). Impaired oxygen-sensitive regulation of mitochondrial biogenesis within the von Hippel-Lindau syndrome. Nature Metabolism, 4(6), 739\u2013758. https:\/\/doi.org\/10.1038\/s42255-022-00593-x","journal-title":"Nature Metabolism"},{"issue":"1","key":"10370_CR131","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cmet.2025.11.013","volume":"38","author":"G Li","year":"2026","unstructured":"Li, G., Pan, W., Wu, L., Cai, Z., Chen, H., Wu, X., et al. (2026). Mitochondrial VHL rewires cell metabolism in hypoxia. Cell Metabolism, 38(1), 174-191 e177. https:\/\/doi.org\/10.1016\/j.cmet.2025.11.013","journal-title":"Cell Metabolism"},{"issue":"41","key":"10370_CR132","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2408549121","volume":"121","author":"LA Stransky","year":"2024","unstructured":"Stransky, L. A., Gao, W., Schmidt, L. S., Bi, K., Ricketts, C. J., Ramesh, V., et al. (2024). Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: Initial experience and lessons learned. Proceedings of the National Academy of Sciences of the United States of America, 121(41), Article e2408549121. https:\/\/doi.org\/10.1073\/pnas.2408549121","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10370_CR133","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1007\/s10815-023-02925-6","volume":"40","author":"F Barrett","year":"2023","unstructured":"Barrett, F., Shaw, J., Besser, A. G., Grifo, J. A., & Blakemore, J. K. (2023). Preimplantation genetic testing for monogenic disorders: Clinical experience with BRCA1 and BRCA2 from 2010\u20132021. Journal of Assisted Reproduction and Genetics, 40(11), 2705\u20132713. https:\/\/doi.org\/10.1007\/s10815-023-02925-6","journal-title":"Journal of Assisted Reproduction and Genetics"},{"issue":"3","key":"10370_CR134","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1089\/gtmb.2025.0031","volume":"29","author":"L Wang","year":"2025","unstructured":"Wang, L., He, X., Huang, X., Qiu, P., Ji, H., Ding, L., et al. (2025). Preimplantation genetic testing in a family with neurofibromatosis type 1. Genetic Testing and Molecular Biomarkers, 29(3), 54\u201362. https:\/\/doi.org\/10.1089\/gtmb.2025.0031","journal-title":"Genetic Testing and Molecular Biomarkers"},{"issue":"7","key":"10370_CR135","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.cell.2025.01.046","volume":"188","author":"Q Jiang","year":"2025","unstructured":"Jiang, Q., Braun, D. A., Clauser, K. R., Ramesh, V., Shirole, N. H., Duke-Cohan, J. E., et al. (2025). HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. Cell, 188(7), 1807-1827 e1834. https:\/\/doi.org\/10.1016\/j.cell.2025.01.046","journal-title":"Cell"},{"issue":"8054","key":"10370_CR136","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","volume":"639","author":"DA Braun","year":"2025","unstructured":"Braun, D. A., Moranzoni, G., Chea, V., McGregor, B. A., Blass, E., Tu, C. R., et al. (2025). A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature, 639(8054), 474\u2013482. https:\/\/doi.org\/10.1038\/s41586-024-08507-5","journal-title":"Nature"},{"issue":"3","key":"10370_CR137","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41591-025-04182-9","volume":"32","author":"AM D'Alise","year":"2026","unstructured":"D\u2019Alise, A. M., Willis, J., Duzagac, F., Hall, M. J., Cruz-Correa, M., Idos, G. E., et al. (2026). Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: A phase 1b\/2 trial. Nature medicine, 32(3), 1002\u20131011. https:\/\/doi.org\/10.1038\/s41591-025-04182-9","journal-title":"Nature medicine"},{"issue":"8016","key":"10370_CR138","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J., Adler, J., Dunger, J., Evans, R., Green, T., Pritzel, A., et al. (2024). Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature, 630(8016), 493\u2013500. https:\/\/doi.org\/10.1038\/s41586-024-07487-w","journal-title":"Nature"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10370-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10370-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10370-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:22:53Z","timestamp":1786591373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10370-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":138,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["10370"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10370-x","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"57"}}